ALK and non-small cell lung carcinoma: To date, the treatment for advanced ALK-positive NSCLC gives preference to an upfront use of second-generation ALK TKIs such as alectinib or brigatinib, due to longer PFS, longer IC PFS, and advantage over OS-although immature; the third-generation ALK TKI lorlatinib is used as a rescue, at systemic progression, leading to a sequencing strategy of treatment.